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There	is	an	increasing	evidence	that	deficiency	of	
DNA	repair	is	one	of	the	factor	of	carcinogenesis.	As-
sessment	of	total	repair	capability	is	now	widespread	
phenotypical	marker	for	predisposition	to	cancer.	It	is	
based	on	in vitro	use	of	challenge	mutagen	to	unmask	
latent	genetic	instability	and	repair	insufficiency.	Two	
widely	used	methods	for	detecting	genomic	instability	
in	lymphocytes	are	applied	—	the	mutagen-sensitiv-
ity	assay	and	the	comet	assay	[1–3].	Five	well	known	
mechanisms	of	DNA	repair	may	have	a	different	con-
tribution	to	total	repair	capability	—	direct	enzymatic	
inactivation	of	DNA	damage;	nucleotide	excision	repair	
(NER),	base	excision	repair	 (BER),	mismatch	repair	
(MMR)	and	double	strand	breaks	repair.
Gynecological	cancers	 (endometrial,	ovarian	and	
uterine	cancers)	is	the	leading	cause	of	cancer	death	
among	women	[4,	also	see www.cancer.org/statistics/].	
Endometrial	and	ovarian	cancers	are	 included	 in	so	
called	hereditary	nonpolyposis	colon	cancer	spectrum	
(HNPCC	spectrum)	which	 is	characterized	by	MMR	
deficiency	[5,	6].	In	turn,	MMR	unsufficiency	has	been	
shown	to	be	associated	with	tolerance	of	cells	to	some	
chemical	substances	especially	to	alkylating	agents	[7].	
This	tolerance	appears	to	be	expressed	as	resistance	to	
genotoxic	effect	of	the	agents	[8].	Therefore	genotoxic	
resistance	to	alkylating	agents	may	be	a	predictive	of	
low	level	of	MMR	activity,	chemoresistance	and	aggres-
siveness	of	cancer.
Early	we	have	shown	that	human	colorectal	tumor	
cells	were	resistant	to	genotoxic	effect	of	methylating	
agent	N-metyl-N-nitrosourea	(MNU)	[9].	In	this	study	
we	utilized	an	in vitro	mutagen	sensitivity	assay	which	
used	MNU	as	 the	challenge	mutagen	and	neutral	
comet	assay	to	estimate	DNA	double	strand	breaks	
24	h	after	pulse-treatment	of	cells	with	the	agent.	Here	
using	this	approach	we	aimed	to	study	responses	of	
stimulated	and	 resting	 lymphocytes	 to	methylating	
agent	MNU	and	to	compare	sensitivity	to	this	agent	of	
healthy	donor	lymphocytes	and	lymphocytes	derived	
from	patients	with	gynecological	cancer.
MATERIALS AND METHODS
Patients and lymphocyte isolation and treat-
ment.	 Venous	blood	samples	were	obtained	 from	
healthy	donors	and	patients	with	gynecological	can-
cer.	All	patient	gave	 informed	written	concent.	Mean	
age	of	donors	(n	=	9,	 females)	was	36	years	(range:	
29–43	years).	All	studied	patients	(n	=	10,	females)	were	
cured	in	the	Department	of	Gynecology	(N.N.	Blokhin	
Cancer	Research	Center,	Moscow).	Mean	age	of	pa-
tients	was	55	years	ranging	from	32	to	71	years	(ovarian	
cancer,	n	=	6,	and	uterine	cancer,	n	=	4).	
Blood	samples	were	 taken	before	any	 therapy.	
Lymphocytes	were	isolated	by	centrifugation	(800	g,	
30	min,	at	RT)	of	heparinized	samples	of	blood	(5–
10	ml)	through	a	cashion	of	ficoll-urografine	solution	
with	 the	density	of	1.077	g/ml.	Pellets	of	cells	were	
washed	twice	 in	PBS	and	suspended	 in	RPMI-1640	
supplemented	with	L-glutamine	 (3	mg/ml),	20%	of	
fetal	bovine	serum,	antibiotics	and	10	μg/ml	phytohe-
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magglutinin	(Gibco_BRL,	USA).	Suspensions	(5	ml	in	
sterile	centrifuge	tubes,	1	×	106/tube)	were	incubated	
for	24	h	in	air	atmosphere	containing	5%	CO2,	at	37	°C.	
All	experiments	were	performed	in	parallel	on	stimu-
lated	and	nonstimulated	lymphocytes.	MNU	(obtained	
from	the	Institute	of	Organic	Chemistry,	Moscow,	Rus-
sia)	was	dissolved	in	distilled	H2O	just	before	addition	
to	cells.	Before	MNU	 treatment	 lymphocytes	were	
incubated	1	h	with	20	μM	O6-benzylguanine	(O6-bzG,	
Sigma).	This	concentration	was	2-fold	higher	of	that	
completely	 inhibiting	O6-methylguanine-transferase	
(MGMT)	 in	human	 tumor	cells	 [9].	BrUdr	 (as	stock	
solution	in	dimethyl	sulfoxide,	3.1	mg/ml)	was	added	
simultaneously	with	MNU	up	to	the	final	concentration	
of	100	μg/ml.	Cells	were	not	washed	from	the	drugs	
during	24	h	incubation	at	37	°C.
Quantification of apoptosis. The	 fraction	 of	
apoptotic	cells	was	measured	with	two	assays	repre-
senting	early	and	late	(executive)	phases	of	the	apop-
totic	response	on	genotoxic	drug	treatment:	Annexin	
V-FITC	Detection	kit	(R	&	D	Systems	GmbH,	Germany),	
allowing	detection	with	fluorescent	microscopy	of	cell	
surface	changes	in	apoptotic	cells;	live/dead	double	
staining	kit,	allowing	to	detect	the	cells	with	chromatin	
condensation	and	nucleus	fragmentation.	Cells	were	
stained	with	mixture	of	two	dyes,	acridine	orange	and	
propidium	iodide,	and	visualized	in	fluorescent	micro-
scope.	Both	assays	 in	detailes	were	 the	same	as	 in	
protocols	for	the	kits	(http://www.merckbiosciences.
co.uk/product/QIA76).
Comet	assay.	Neutral	comet	assay	was	performed	
as	previously	described	[10]	with	some	modifications	
made	to	detect	DNA-comets	contaning	BrUdr.	In	short,	
100	μl	of	cells	(106	cells	per	ml)	in	PBS	were	mixed	with	
200	μl	of	1%	low	melting	point	agarose	at	37	°C.	70	μl	
of	the	mixture	were	carefully	layered	onto	microscope	
slide,	covered	with	cover	glass	(size	24	x	24	mm	and	
allowed	to	solidify	on	an	ice-cold	surface.	The	slides	
were	placed	in	a	lysis	solution	(2.5	M	LiCl,	30	mM	EDTA,	
10	mM	Tris-HCl,	0.1%	Li-dodecylsulfate,	0.03	mg/ml	
proteinase	K,	pH	8.0).	After	 incubation	at	37	 °C	 for	
14–18	h	the	lysis	solution	was	replaced	by	buffer	(2.5	M	
NaCl,	0.1	M	EDTA,	10	mM	Tris-HCl,	1%	Triton-X100,	
10%	dimethyl	sulfoxide,	pH	10)	for	at	least	3	h	at	8	°C.	
Slides	were	placed	in	a	horizontal	electrophoresis	tank	
filled	with	fresh	TAE	buffer,	pH	8.3	and	left	to	equilibrate	
for	40	min	before	electrophoresis.	Electrophoresis	was	
conducted	for	30	min	at	0.5	V/cm.	After	electrophoresis,	
the	slides	were	placed	in	alkaline	solution	(0.3	M	NaOH,	
1	mM	EDTA,	pH	13)	for	10	min	at	8	°C.	The	slides	were	
flooded	with	 three	changes	of	neutralization	buffer	
(0.4	M	Tris,	pH	7.4),	followed	by	one	wash	in	PBS,	and	
drained	with	paper.	For	localization	of	BrUdr	incorpo-
rated	in	DNA-comets,	25	μl/gel	of	mouse	monoclonal	
anti-BrdUrd	antibody	(10	μg/ml;	Boehringer	Mannheim)	
were	added,	covered	with	coverslips	(18	x	18	mm)	and	
incubated	 for	1	h	 in	dark	at	RT.	After	 removal	of	 the	
coverslips,	the	primary	antibody	was	gently	washed	off	
with	three	changes	of	PBS	and	one	wash	with	PBS	+	
0.1%	BSA	before	addition	of	25	μl/gel	of	secondary	
antibody	(5	μg/ml	sheep	anti-mouse	IgG,	fluorescein	
conjugated;	Boehringer	Mannheim),	which	was	incu-
bated	and	washed	off	as	before.	Slides	were	dried	on	
air,	dehydrated	with	methanol	and	kept	in	dark	at	RT	for	
at	least	1	month	without	any	changes	in	fluorescence.	
For	 image	analysis,	slides	were	counterstained	with	
propidium	iodide	1	μg/ml	of	antifade	and	visualized	in	
fluorescent	microscope	(Micromed,	LOMO,	Russia),	
with	excitation	at	 the	wave	 length	of	480	nm,	barrier	
filter	535	nm.	Densitometric	and	geometric	parameters	
of	each	comet	were	calculated	with	comet	analysis	
program	CASP	[11].	Propidium	iodide	stained	comets	
were	visualized	using	excitation	 the	wave	 length	of	
540		nm	and	emission	the	wave	length	of	635	nm.	Olive	
tail	moments	(mt)	were	calculated	for	≥120	comets	on	
each	slide.	Presented	numbers	of	MNU-induced	DNA	
double	strand	breaks	was	calculated	by	subtracting	
comet	tail	moment	for	untreated	cells	from	the	same	
for	MNU-treated	ones.	Mean	difference	was	calibrated	
using	gamma-irradiation	of	resting	human	lymphocytes	
(°C)	with	doses	0–40	Gy	and	yield	of	double	strand	
breaks	to	be	50	per	diploid	genome	within	this	range	
of	doses	[12].
Index of proliferation.	Fraction	of	proliferating	
lymphocytes	after	48	h	stimulation	was	determined	
as	the	fraction	of	BrUdr-positive	comets	after	BrUdr	
incorporation	in	DNA	during	24	h	incubation	with	cells.	
General	number	of	comets	was	counted	using	fluores-
cence	of	PI-stained	comets.
Statistics.	Statistical	analysis	was	performed	using	
STATISTICA,	version	5.0	software.	Significance	of	differ-
ences	between	case	and	control	parameters	was	calcu-
lated	using	a	Mann	—	Whitney’s	U-test	and	considering	
p	<	0.05	as	indicator	of	significant	differences.
RESULTS AND DISCUSSION
Cytotoxic and genotoxic effects of MNU on 
resting and proliferating lymphocytes.	 In	 this	
study	we	aim	 to	compare	 the	 responses	of	human	
lymphocytes	 to	 short-term	MNU	 treatment,	 imply-
ing	 lymphocytes	of	healthy	donors	as	a	control	and	
lymphocytes	from	cancer	patients	as	a	case.	These	
responses	 include	 activation	 of	 2	 excision	 repair	
pathways	—	base	excision	repair	(BER)	and	mismatch	
repair	 (MMR)	 [13].	To	discriminate	contributions	of	
each	pathway	in	the	responses,	we	compared	geno-	
and	cytotoxicity	of	MNU	on	resting	and	proliferating	
(PHA	stimulated)	lymphocytes.	For	measurement	of	
DNA	damage	in	proliferating	cells	we	vizualised	anti-
BrUdr	antibody-FITC	labelled	comets	(Fig.	1,	b)	and	
for	resting	lymphocytes	we	counted	propidium	iodide	
stained	comets	(Fig.	1,	a).
Fig.	2	summarizes	the	results	of	detection	of	DSB	
(a, d)	and	apoptosis	(b, c, e,	and	f)	in	stimulated	and	
unstimulated	 lymphocytes	 in	 response	 to	MNU.	The	
first	 finding	 following	 these	data	 is	 that	unstimulated	
lymphocytes	are	tolerant	to	geno-	and	cytotoxic	action	
of	MNU	 in	 the	used	concentration	 (see	Fig.	2,	d–f):	
exposure	to	MNU	(500	μM)	had	 little	or	no	effect	on	
resting	peripheral	blood	 lymphocytes.	 In	contrast	 to	
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resting	cells,	proliferating	lymphocytes	show	significant	
genotoxicity	of	MNU	followed	by	increased	apoptotic	
death	of	cells	(see	Fig.	2,	a–c).	It	means	that	BER	and	
nucleotide	excision	repair	are	unlikely	to	be	involved	in	
delayed	geno-	and	cytotoxic	effects	of	MNU	in	stimu-
lated	lymphocytes.	This	conclusion	is	supported	by	the	
data	obtained	with	gamma-irradiated	human	lympho-
cytes	[14]:	no	difference	in	the	rate	of	DNA	repair	ca-
pacity	after	irradiation	between	resting	and	proliferating	
peripheral	blood	lymphocytes	was	observed.	Moreover,	
the	observed	delay	of	toxic	effect	of	MNU	may	reflect	
its	association	with	postreplicative	DNA	repair,	MMR,	
rather	than	with	BER	and	NER	mechanisms.	The	second	
finding	illustrated	by	Fig.	2	is	that	the	time	of	appearance	
of	DNA	double	strand	breaks	coincides	with	the	time	of	
appearance	of	annexin	V	positive	lymphocytes,	the	sign	
of	early	phase	of	apoptotic	death	(see	Fig.	2,	a	and	b).	
In	addition	to	this,	morphological	markers	of	apoptosis	
in	stimulated	lymphocytes	are	displayed	24	h	later	DNA	
breaks	appearance	(see	Fig.	2,	a vs c).	This	indicates	
DNA	double	strand	breaks	(DSBs)	to	be	an	initiating	sig-
nal	for	apoptosis	induced	by	MNU.	The	breaks	occured	
prior	to	apoptosis	and	likely	to	be	a	result	of	functioning	
of	active	MMR	mechanism	[13,	15].	MNU,	monofunc-
tional	SN1	methylating	agent,	induces	two	main	adducts	
in	DNA	N-methylated	bases	and	O6-methylated	guanine	
(O6-meG)	[16,	17].	The	first	is	repaired	by	BER	pathway	
prior	 to	 replication	 [18].	The	 later	 is	 repaired	by	O6-
methylguanine	DNA-methyltransferase	(O6MGMT)	and	
by	MMR	pathway.	As	MGMT	is	inhibited	by	including	in	
the	culture	of	O6-benzylguanine,	O6-meG	is	repaired	by	
postreplication	MMR	mechanism	only	[19].	MMR-pro-
cessing	of	O6-meG	results	in	single	strand	gap	opposide	
the	modified	guanine.	Double	strand	break	(secondary	
DSB)	may	be	formed	either	due	to	endonuclease	attack	
or	during	the	following	cycle	of	replication.	Therefore	
we	conclude	that	the	secondary	DNA	breaks	(observed	
24	h	after	MNU	treatment	of	lymphocytes)	may	be	an	
indicator	of	functional	activity	of	MMR	in	stimulated	lym-
phocytes.	This	conclusion	is	supported	by	the	results	
of	our	previous	study	reported	a	correlation	between	
number	of	secondary	MNU-induced	DSBs	and	MMR	
activity	in	3	tumor	cell	lines	[9].
Fig. 1. DNA-comets	 stained	with	propidium	 iodide	 (a)	 and	
comets	produced	by	BrUdr-labelled	cells	and	stained	with	FITC-
conugated	anti-BrUdr	monoclonal	antibodies	(b)
Fig. 2. Genotoxic	and	cytotoxic	effects	of	MNU	on	PHA	stimu-
lated	(a, b, c)	and	resting	(d, e, f)	human	blood	lymphocytes.	
Light-grey	columns		—	intact	lymphocytes,	dark-grey	columns	—	
MNU/O6-bzG	(500/20	μM)	treated	lymphocytes.	a	and	d:	DNA	
damage	(double	strand	breaks);	b	and	e:	frequencies	of	apop-
totic	cells	detected	by	annexin	V-FITC	complex	at	24	and	48	h	
after	MNU	treatment;	c and	f:	the	same	as	b and	e	but	apoptosis	
was	measured	according	to	morphological	criteria
Genotoxicity of MNU on lymphocytes from pa-
tients with gynecological cancer.	Although	number	
of	studied	persons	does	not	permit	to	compare	strictly	
distributions	 for	 the	case	and	control	persons,	mean	
values	of	DNA	damage	reveal	significant	difference	be-
tween	them.	Fig.	3	shows	that	average	number	of	DSBs	
in	peripheral	blood	lymphocytes	derived	from	patients	
with	gynecological	cancers	 is	about	4-fold	 lower	than	
that	for	lymphocytes	of	healthy	donors	(p	=	0.044)	but	
significantly	higher	 than	for	MMR-deficient	colorectal	
tumor	HCT116	cells.	MMR-deficiency	of	HCT116	cells	is	
a	result	of	mutation	in	hMLH1 that	inactivates	the	protein	
encoded	by	this	gene	[20].	All	cases	studied	here	were	
unlikely	to	be	familial	cancers	and	appear	not	to	harbour	
germline	mutations	 in	any	MMR	genes.	Therefore	the	
observed	decrease	of	MMR	activity	in	lymphocytes	from	
cancer	patients	may	be	associated	with	decreased	ex-
pression	of	MMR	proteins	due	to	abnormal	methylation	of	
MMR	genes	[21].	It	should	be	pointed	out	that	according	
to	our	data	lymphocytes	from	cancer	patients	are	cha-
racterized	by	decreased	proliferative	indeces	compared	
to	normal	donors:	12.8	±	11%	vs	27.2	±	8.1%	(p	=	0.048).	
As	for	sensitivity	of	proliferation	to	MNU,	cancer	patients	
were	resistant	 to	 the	mutagen	treatment	(proliferative	
indeces	for	 intact	vs	 treated	 lymphocytes	were	12.8	±	
11%	vs	12.4	±	9.3%,	p	=	0.93)	in	contrast	to	normal	do-
nors	(respectively,	27.2	±	8.1%	vs	18.7	±	7.5%,	p	=	0.06).	
This	result	is	in	agreement	with	reduced	MMR	activity	in	
case	lymphocytes	compared	to	control	cells.
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Fig. 3. Average	numbers	±	SEM	of	double	strand	breaks	induced	
24	h	after	MNU	(500	μM)	pulse-treatment	of	cells.	1	—	PHA	
stimulated	 lymphocytes	derived	 from	health	donors	 (n	=	9),	
2	—	 the	same	 from	patients	with	gynecological	cancers	 (n	=	
10),	3	—	MMR-deficient	HCT116	cells	(n	=	6).	1	h	before	MNU	
treatment,	O6-bzG	(20	μM)	was	added	to	cells
If	the	observed	reduction	of	functional	activity	of	
MMR	in	lymphocytes	is	not	only	associated	with	can-
cer,	but	is	a	preceding	event,	then	genotoxic	sensitivity	
of	peripheral	blood	lymphocytes	to	MNU	may	serve	as	
a	marker	and	predictor	for	the	risk	of	development	of	
gynecological	cancer	[22].
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ЧУВСТВИТЕЛЬНОСТЬ ЛИМФОЦИТОВ 
ЧЕЛОВЕКА К ГЕНОТОКСИЧЕСКОМУ ДЕЙСТВИЮ 
МЕТИЛНИТРОЗОМОЧЕВИНЫ: ВОЗМОЖНАЯ СВЯЗЬ 
С ОпУхОЛЯМИ ЖЕНСКОЙ пОЛОВОЙ СФЕРЫ
Цель: исследование эффекта метилнитрозомочевины (МНМ) на ФГА-стимулированные лимфоциты и в состоянии 
покоя здоровых доноров и пациенток с опухолями женской половой сферы. Методы: цитотоксический эффект МНМ 
(апоптотическая гибель лимфоцитов) оценивали по двум показателям — взаимодействию клеток с комплексом an-
nexin V-FITC и по морфологическим изменениям ядра клеток после их окрашивания смесью 2 ДНК-тропных красителей. 
Генотоксический эффект МНМ, вторичные двунитевые разрывы ДНК (ДР) определяли с помощью метода нейтральных 
ДНК-комет. Использовали стандартный вариант метода и модифицированный для подсчета комет, формируемых только 
делящимися лимфоцитами, меченными BrUdr. Долю таких комет представляли как индекс пролиферации клеток. Результаты: 
лимфоциты в состоянии покоя устойчивы к гено- и цитотоксическому эффектам МНМ. В пролиферирующих клетках в ответ 
на воздействие МНМ формировались вторичные разрывы ДНК (р < 0,01) и возрастала частота появления апоптотических 
клеток (р < 0,05). Генотоксический эффект МНМ на стимулированные лимфоциты больных онкологического профиля в 
4 раза ниже, чем на лимфоцитах здоровых доноров. Лимфоциты пациенток не изменяли пролиферативный индекс в ответ на 
действие МНМ; в лимфоцитах здоровых доноров действие МНМ вызывало 2-кратное снижение пролиферативного индекса. 
Выводы: установлена связь между гено- и цитотоксическим ответом лимфоцитов на действие МНМ и наличием опухоли. 
Предполагается, что генотоксический эффект МНМ связан с процессом пострепликативной коррекционной репарации.
Ключевые слова: опухоли женской половой сферы, лимфоциты, коррекционная репарация (MMR), метилирующие агенты, 
двунитевые разрывы ДНК.
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